FindTrial
Sign In

Rituximab SC

DRUG5 trials

Sponsors

Hoffmann-La Roche, Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH, The Lymphoma Academic Research Organisation, Canadian Cancer Trials Group

Conditions

Follicular LymphomaLymphoma, B-CellLymphoma, Large B-Cell, DiffuseNon-Hodgkin's LymphomaPosttransplant Lymphoproliferative Disorder

Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
RecruitingNCT04161248
Canadian Cancer Trials GroupLymphoma, B-Cell
Start: 2020-09-02End: 2026-12-31Target: 18Updated: 2026-02-02

Phase 2

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
CompletedNCT02042391
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbHPosttransplant Lymphoproliferative Disorder
Start: 2015-02-03End: 2022-07-13Updated: 2022-08-25
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
CompletedNCT04660799
Hoffmann-La RocheLymphoma, Large B-Cell, Diffuse
Start: 2021-02-24End: 2022-10-11Updated: 2023-10-12

Phase 3

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
CompletedNCT01200758
Hoffmann-La RocheNon-Hodgkin's Lymphoma
Start: 2011-02-15End: 2017-10-31Updated: 2018-11-27
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
CompletedNCT02303119
The Lymphoma Academic Research OrganisationFollicular Lymphoma
Start: 2015-02-02End: 2021-06-29Updated: 2023-01-10

Related Papers

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma
Blood2025-11-03
Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial
Leukemia & lymphoma/Leukemia and lymphoma2025-01-071 citations
Single-Cell Longitudinal Characterization of FL Heterogeneity and Residual Disease in the Bone Marrow from Low-Tumor Burden FL Enrolled in the Flirt Clinical Trial
Blood2023-11-02
PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL
HemaSphere2023-08-01
PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB IN CHINESE PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL
Hematological Oncology2023-06-01
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
2022-08-1629 citations
Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.
Journal of Clinical Oncology2022-06-011 citations
Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial
Blood2021-11-05
Follicular Lymphoma Evaluation Index (<scp>FLEX</scp>): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
American Journal of Hematology2020-08-2846 citations
Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial.
Journal of Clinical Oncology2020-05-202 citations
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
Cancer Chemotherapy and Pharmacology2020-03-2818 citations
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
The Journal of Clinical Pharmacology2018-12-1936 citations
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
2017-05-0283 citations
Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study
Blood2016-12-021 citations
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
PLoS ONE2016-06-30100 citations
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
2014-02-1090 citations
Time Savings With Rituximab Subcutaneous (SC) Injection Vs Rituximab Intravenous (IV) Infusion: Final Analysis From a Time-and-Motion Study In 8 Countries
Blood2013-11-157 citations